Compare RITM & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RITM | BLLN |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.6B |
| IPO Year | 2012 | 2025 |
| Metric | RITM | BLLN |
|---|---|---|
| Price | $8.46 | $101.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $13.00 | ★ $129.00 |
| AVG Volume (30 Days) | ★ 6.4M | 527.4K |
| Earning Date | 10-23-2026 | 11-04-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ 103.40 |
| EPS | 0.16 | ★ 0.48 |
| Revenue | ★ $4,590,228,000.00 | $305,112,000.00 |
| Revenue This Year | $54.48 | $49.05 |
| Revenue Next Year | $7.79 | $26.16 |
| P/E Ratio | ★ $53.97 | $204.23 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $8.31 | $61.96 |
| 52 Week High | $12.15 | $150.44 |
| Indicator | RITM | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 48.81 |
| Support Level | $8.43 | $88.85 |
| Resistance Level | $9.49 | $108.50 |
| Average True Range (ATR) | 0.22 | 6.85 |
| MACD | 0.01 | -0.56 |
| Stochastic Oscillator | 13.89 | 40.14 |
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights), loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.